A shrinkage estimator for subgroup analysis without the exchangeability assumption

References

• Carroll, K. J., and T. R. Fleming. 2013. Statistical evaluation and analysis of regional interactions: The PLATO trial case study. Statistics in Biopharmaceutical Research 5 (2):91–101. doi:10.1080/19466315.2013.783878.
   Web of Science ®Google Scholar
• Cui, L., H. M. J. Hung, S. J. Wang, and Y. Tsong. 2002. Issues related to subgroup analysis in clinical trials. Journal of Biopharmaceutical Statistics 12 (3):347–358. doi:10.1081/BIP-120014565.
   PubMedGoogle Scholar
• Gamalo-Siebers, M., R. Tiwari, and L. LaVange. 2016. Flexible shrinkage estimation of subgroup effects through Dirichlet process priors. Journal of Biopharmaceutical Statistics 26 (6):1040–1055. doi:10.1080/10543406.2016.1226327.
   PubMed Web of Science ®Google Scholar
• Grouin, J.-M., M. Coste, and J. Lewis. 2005. Subgroup analyses in randomized clinical trials: Statistical and regulatory issues. Journal of Biopharmaceutical Statistics 15 (5):869–882. doi:10.1081/BIP-200067988.
   PubMed Web of Science ®Google Scholar
• Henderson, N. C., T. A. Louis, C. Wang, and R. Varadhan. 2016. Bayesian analysis of heterogeneous treatment effects for patient-centered outcomes research. Health Services and Outcomes Research Methodology 16 (4):213–233. doi:10.1007/s10742-016-0159-3.
   PubMedGoogle Scholar
• Hsu, -Y.-Y., J. Zalkikar, and R. C. Tiwari. 2017. Hierarchical Bayes approach for subgroup analysis. Statistical Methods in Medical Research 28:275–288. doi:10.1177/0962280217721782.
   PubMed Web of Science ®Google Scholar
• Huang, Y., W.-J. Chang, and C.-F. Hsiao. 2013. An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials. Pharmaceutical Statistics 12 (2):59–64. doi:10.1002/pst.1553.
   PubMed Web of Science ®Google Scholar
• Jones, H. E., D. I. Ohlsson, B. Neuenschwander, A. Racine, and M. Branson. 2011. Bayesian models for subgroup analysis in clinical trials. Clinical Trials 8 (2):129–143. doi:10.1177/1740774510396933.
   PubMed Web of Science ®Google Scholar
• Julian, D. G. 2000. Debate: A subversive view of subsets – A dissident clinician’s opinion. Current Controlled Trials in Cardiovascular Medicine 1 (1):28–30. doi:10.1186/CVM-1-1-028.
   PubMedGoogle Scholar
• Lagakos, S. W. 2006. The challenge of subgroup analyses — Reporting without distorting. New England Journal of Medicine 354 (16):1667–1669. doi:10.1056/NEJMp068070.
   PubMed Web of Science ®Google Scholar
• Lipsky, A. M., M. Gausche-Hill, M. Vienna, and R. J. Lewis. 2010. The importance of “shrinkage” in subgroup analysis. Annals of Emergency Medicine 55:544–552. doi:10.1016/j.annemergmed.2010.01.002.
   PubMed Web of Science ®Google Scholar
• Pennello, G., and M. Rothmann. 2018. Bayesian subgroup analysis with hierarchical models. In Biopharmaceutical applied statistics symposium, ICSA book series in statistics, ed. K. Peace, D. G. Chen, and S. Menon. 175–192. Singapore: Springer.
   Google Scholar
• Peto, R. 2011. Current misconception 3: That subgroup-specific trial mortality results often provide a good basis for individualising patient care. British Journal of Cancer 104 (7):1057–1058. doi:10.1038/bjc.2011.79.
   PubMed Web of Science ®Google Scholar
• Pfeffer, M. A., and J. A. Jarcho. 2006. The charisma of subgroups and the subgroups of CHARISMA. New England Journal of Medicine 354 (16):1744–1746. doi:10.1056/NEJMe068061.
   PubMed Web of Science ®Google Scholar
• Pocock, S. J., S. E. Assmann, L. E. Enos, and L. E. Kasten. 2002. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems. Statistics in Medicine 21 (19):2917–2930. doi:10.1002/sim.1296.
   PubMed Web of Science ®Google Scholar
• Quan, H., M. Li, W. J. Shih, S. P. Ouyang, J. Chen, J. Zhang, and P.-L. Zhao. 2013. Empirical shrinkage estimator for consistency assessment of treatment effects in multi-regional clinical trials. Statistics in Medicine 32 (10):1691–1706. doi:10.1002/sim.5543.
   PubMed Web of Science ®Google Scholar
• Simon, R. 2002. Bayesian subset analysis: Application to studying treatment-by-gender interactions. Statistics in Medicine 21 (19):2909–2916. doi:10.1002/sim.1295.
   PubMed Web of Science ®Google Scholar
• Sleight, P. 2000. Debate: Subgroup analysis in clinical trials – Fun to look at, but don’t believe them! Current Controlled Trials in Cardiovascular Medicine 1 (1):25–27. doi:10.1186/CVM-1-1-025.
   PubMedGoogle Scholar
• Varadhan, R., and S.-J. Wang. 2016. Treatment effect heterogeneity for univariate subgroups in clinical trials: Shrinkage, standardization, or else. Biometrical Journal 58 (1):133–153. doi:10.1002/bimj.201400102.
   PubMed Web of Science ®Google Scholar
• Wedel, H., D. DeMets, P. Deedwania, B. Fagerberg, S. Goldstein, S. Gottlieb, A. Hjalmarson, J. Kjekshus, F. Waagstein, and J. Wikstrand on behalf of the MERIT-HF Study Group. 2001. Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial. American Heart Journal 142 (3):502–511. doi:10.1067/mhj.2001.117600.
   PubMed Web of Science ®Google Scholar
• White, I. R., S. J. Pocock, and D. Wang. 2005. Eliciting and using expert opinions about influence of patient characteristics on treatment effects: A Bayesian analysis of the CHARM trials. Statistics in Medicine 24 (24):3805–3821. doi:10.1002/sim.2420.
   PubMed Web of Science ®Google Scholar
• Yusuf, S., J. Wittes, J. Probstfield, and H. A. Tyroler. 1991. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Journal of the American Medical Association 266:93–98. doi:10.1001/jama.1991.03470010097038.
   PubMed Web of Science ®Google Scholar